Evocatal Invests in High-Throughput Technology
News Dec 02, 2010
Together with the scientific advisory board and evocatal’s 17-strong team CSO Dr. Christian Leggewie opens up the newly established high-throughput laboratory in the Life Science Centre Duesseldorf.
One of the pioneers in development and successful use of automated high- and ultrahigh-throughput technology in the field chiral synthesis of ultrapure fine chemicals is Prof. Manfred T. Reetz, who chairs evocatal’s scientific advisory board since 2008. “Not at least for this reason our HTS-lab will carry the name of our advisory board’s chairman”, CEO Dr. Thorsten Eggert comments the dedication.
The investment enables evocatal to reduce development periods for customized biocatalysts immensely. This applies for projects with cooperation partners as well as for supplying efficient enzymes for the internal production of fine chemicals.
“Due to the Prof.-Reetz-Lab our customers will get a faster access to our comprehensive metagenome and enzyme libraries”, says Dr. Michael Puls, Managing Director and CMO of evocatal. “A short time-to-market is of utmost significance – thus we can now ensure our customers a long-term advantage in competition by automizing our development processes”, adds Dr. Puls.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE